$CDXS
CODEXIS, INC.

2013 Q1 Form 10-K Financial Statement

#000144530513000770 Filed on April 02, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2011 Q4 2011 Q3
Revenue $11.48M $33.49M $33.28M
YoY Change -63.13% 12.36% 22.77%
Cost Of Revenue $5.665M $13.07M $9.958M
YoY Change -55.19% 60.73% 16.33%
Gross Profit $5.816M $20.43M $23.32M
YoY Change -68.55% -5.82% 25.74%
Gross Profit Margin 50.66% 60.99% 70.08%
Selling, General & Admin $8.124M $9.782M $8.871M
YoY Change -13.53% 13.09% 11.73%
% of Gross Profit 139.68% 47.89% 38.03%
Research & Development $7.322M $15.55M $16.79M
YoY Change -55.21% 16.46% 28.43%
% of Gross Profit 125.89% 76.11% 71.97%
Depreciation & Amortization $1.798M $3.010M $2.850M
YoY Change -18.38% 15.33% 45.41%
% of Gross Profit 30.91% 14.74% 12.22%
Operating Expenses $21.11M $38.40M $35.62M
YoY Change -45.0% 74.61% 69.51%
Operating Profit -$9.630M -$17.97M -$12.29M
YoY Change 32.83% 5890.0% 399.63%
Interest Expense $30.00K $80.00K $80.00K
YoY Change -62.5% 166.67% 33.33%
% of Operating Profit
Other Income/Expense, Net $85.00K -$300.0K -$410.0K
YoY Change -27.97% 100.0% 925.0%
Pretax Income -$9.688M -$5.123M -$2.668M
YoY Change 32.84% 1064.32% 9.79%
Income Tax -$65.00K $170.0K $70.00K
% Of Pretax Income
Net Earnings -$9.623M -$5.297M -$2.742M
YoY Change 28.48% 959.4% 0.44%
Net Earnings / Revenue -83.82% -15.81% -8.24%
Basic Earnings Per Share
Diluted Earnings Per Share -$254.2K -$147.3K -$76.28K
COMMON SHARES
Basic Shares Outstanding 38.01M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q1 2011 Q4 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.18M $53.48M $49.60M
YoY Change -17.12% -26.13% -50.05%
Cash & Equivalents $31.23M $25.76M $30.10M
Short-Term Investments $12.94M $27.72M $19.50M
Other Short-Term Assets $4.100M $2.300M $2.800M
YoY Change 0.0% 43.75% 47.37%
Inventory $1.686M $4.488M $5.200M
Prepaid Expenses
Receivables $7.412M $18.92M $19.30M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $57.37M $79.23M $77.00M
YoY Change -28.91% -14.07% -35.73%
LONG-TERM ASSETS
Property, Plant & Equipment $14.79M $24.18M $23.30M
YoY Change -38.37% 12.45% 10.95%
Goodwill $3.241M $3.241M
YoY Change
Intangibles $12.09M
YoY Change
Long-Term Investments $1.900M $10.30M $21.00M
YoY Change -78.65% 505.88%
Other Assets $2.701M $972.0K $2.600M
YoY Change 17.43% -62.62% -25.71%
Total Long-Term Assets $36.27M $56.69M $67.60M
YoY Change -32.7% 15.46% 138.87%
TOTAL ASSETS
Total Short-Term Assets $57.37M $79.23M $77.00M
Total Long-Term Assets $36.27M $56.69M $67.60M
Total Assets $93.64M $135.9M $144.6M
YoY Change -30.43% -3.81% -2.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.445M $10.36M $7.500M
YoY Change -50.61% 12.65% -17.58%
Accrued Expenses $4.826M $7.354M $18.30M
YoY Change -68.25% -46.32% 31.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.78M $28.29M $34.40M
YoY Change -46.46% 2.88% -5.49%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.868M $3.455M $3.700M
YoY Change -24.16% -46.85% -51.32%
Total Long-Term Liabilities $3.868M $3.455M $3.700M
YoY Change -24.16% -46.85% -51.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.78M $28.29M $34.40M
Total Long-Term Liabilities $3.868M $3.455M $3.700M
Total Liabilities $21.64M $31.75M $38.10M
YoY Change -43.49% -6.35% -13.21%
SHAREHOLDERS EQUITY
Retained Earnings -$225.2M -$184.7M
YoY Change
Common Stock $4.000K $4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $70.75M $102.7M $106.5M
YoY Change
Total Liabilities & Shareholders Equity $93.64M $135.9M $144.6M
YoY Change -30.43% -3.81% -2.36%

Cashflow Statement

Concept 2013 Q1 2011 Q4 2011 Q3
OPERATING ACTIVITIES
Net Income -$9.623M -$5.297M -$2.742M
YoY Change 28.48% 959.4% 0.44%
Depreciation, Depletion And Amortization $1.798M $3.010M $2.850M
YoY Change -18.38% 15.33% 45.41%
Cash From Operating Activities -$3.487M -$2.900M $2.750M
YoY Change -688.03% 778.79% 3.38%
INVESTING ACTIVITIES
Capital Expenditures $48.00K -$2.930M -$3.620M
YoY Change -97.72% 30.22% 133.55%
Acquisitions
YoY Change
Other Investing Activities $2.500M $1.370M -$1.240M
YoY Change 19.05% -106.37% -102.54%
Cash From Investing Activities $2.452M -$1.560M -$4.860M
YoY Change -27344.44% -93.43% -110.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $263.0K 100.0K 90.00K
YoY Change 179.79% -103.65% -104.43%
NET CHANGE
Cash From Operating Activities -$3.487M -2.900M 2.750M
Cash From Investing Activities $2.452M -1.560M -4.860M
Cash From Financing Activities $263.0K 100.0K 90.00K
Net Change In Cash -$772.0K -4.360M -2.020M
YoY Change -213.86% -83.74% -104.22%
FREE CASH FLOW
Cash From Operating Activities -$3.487M -$2.900M $2.750M
Capital Expenditures $48.00K -$2.930M -$3.620M
Free Cash Flow -$3.535M $30.00K $6.370M
YoY Change 133.49% -98.44% 51.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7545000 USD
CY2010 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-511000 USD
CY2012 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-697000 USD
CY2011 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-771000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3654000 USD
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10364000 USD
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18917000 USD
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7354000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6948000 USD
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31747000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
34172000 USD
CY2010 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
7246000 USD
CY2011 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
7755000 USD
CY2012 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
8908000 USD
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-407000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-136000 USD
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
287792000 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
294128000 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5040000 USD
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9286000 USD
CY2010 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8468000 USD
CY2010 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2686000 USD
CY2010 us-gaap Advertising Expense
AdvertisingExpense
55000 USD
CY2012 us-gaap Advertising Expense
AdvertisingExpense
351000 USD
CY2011 us-gaap Advertising Expense
AdvertisingExpense
113000 USD
CY2011 us-gaap Allowance For Doubtful Accounts Receivable Charge Offs
AllowanceForDoubtfulAccountsReceivableChargeOffs
12000 USD
CY2012 us-gaap Allowance For Doubtful Accounts Receivable Charge Offs
AllowanceForDoubtfulAccountsReceivableChargeOffs
0 USD
CY2010 us-gaap Allowance For Doubtful Accounts Receivable Charge Offs
AllowanceForDoubtfulAccountsReceivableChargeOffs
0 USD
CY2011Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
17000 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
150000 USD
CY2010 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-122000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72396000 USD
CY2011 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2010 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
26000 USD
CY2012 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2010 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1063000 USD
CY2011Q4 us-gaap Assets
Assets
135922000 USD
CY2011Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
200000 USD
CY2012Q4 us-gaap Assets
Assets
99965000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
59769000 USD
CY2012Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
63000 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
79232000 USD
CY2011Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
45000 USD
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6241000 USD
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
41874000 USD
CY2011Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
57090000 USD
CY2012Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
41937000 USD
CY2011Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
56935000 USD
CY2012Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
0 USD
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3509000 USD
CY2011 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3716000 USD
CY2010 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8062000 shares
CY2009Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31785000 USD
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7351000 shares
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8716000 shares
CY2011Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
579000 USD
CY2012Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
109000 USD
CY2012 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
30000 USD
CY2010 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
146000 USD
CY2011 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
39000 USD
CY2012Q4 us-gaap Cash
Cash
7200000 USD
CY2011Q4 us-gaap Cash
Cash
6900000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25762000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32003000 USD
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-46634000 USD
CY2010 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
40611000 USD
CY2012Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6066 shares
CY2011Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35996000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37692000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37692000 shares
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35996000 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2012 us-gaap Comparability Of Prior Year Financial Data
ComparabilityOfPriorYearFinancialData
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain amounts in prior period financial statements related to Shell including related party collaboration revenue (see Note 3), related party receivable and related party deferred revenue, have been reclassified to the corresponding non-related party account, since effective July 1, 2011, Shell is no longer considered a related party (see Note 7). Our investment in CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;"> Solutions (See Note 4), has been reclassified from non-current other assets to non-current marketable securities and the composition of our deferred tax assets have been reclassified to conform to the current period presentation.</font></div></div>
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16923000 USD
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30586000 USD
CY2010 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8323000 USD
CY2012 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, accounts receivable and restricted cash. Cash and cash equivalents, marketable securities and restricted cash are invested through banks and other financial institutions in the United States, as well as in other foreign countries. Such deposits may be in excess of insured limits.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk with respect to accounts receivable exists to the full extent of amounts presented in the consolidated financial statements. We periodically require collateral to support credit sales. We estimate an allowance for doubtful accounts through specific identification of potentially uncollectible accounts receivable based on an analysis of our accounts receivable aging. Uncollectible accounts receivable are written off against the allowance for doubtful accounts when all efforts to collect them have been exhausted. Recoveries are recognized when they are received. Actual collection losses may differ from our estimates and could be material to our consolidated financial position, results of operations, and cash flows.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Supply Risk</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on a limited number of suppliers for our products. We believe that other vendors would be able to provide similar products; however, the qualification of such vendors may require substantial start-up time. In order to mitigate any adverse impacts from a disruption of supply, we attempt to maintain an adequate supply of critical single-sourced materials. For certain materials, our vendors maintain a supply for us. We outsource the commercial scale manufacturing of our products to contract manufacturers with facilities in Austria, India and Italy.</font></div></div>
CY2012 us-gaap Cost Of Goods Sold
CostOfGoodsSold
30647000 USD
CY2011Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7106000 USD
CY2012Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5829000 USD
CY2011Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
13067000 USD
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2010 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
289000 USD
CY2011 us-gaap Cost Of Goods Sold
CostOfGoodsSold
41781000 USD
CY2010 us-gaap Cost Of Goods Sold
CostOfGoodsSold
27982000 USD
CY2012Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
12642000 USD
CY2011Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
11650000 USD
CY2012Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5779000 USD
CY2011Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
9958000 USD
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6397000 USD
CY2011 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
3000 USD
CY2011 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
92000 USD
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
7000 USD
CY2011 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
82000 USD
CY2010 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-17000 USD
CY2012 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
178000 USD
CY2010 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000 USD
CY2011 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
7000 USD
CY2010 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
274000 USD
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
185000 USD
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-62000 USD
CY2011 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2012 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
154000 USD
CY2010 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
258000 USD
CY2011 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
149000 USD
CY2010 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
110000 USD
CY2011 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
149000 USD
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
85000 USD
CY2011Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
53000 USD
CY2012Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0 USD
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3789000 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2186000 USD
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1485000 USD
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1299000 USD
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-7000 USD
CY2011 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2010 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-26000 USD
CY2012Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1297000 USD
CY2011Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2066000 USD
CY2012Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3556000 USD
CY2011Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3128000 USD
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
71712000 USD
CY2011Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
63355000 USD
CY2011Q4 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
0 USD
CY2012Q4 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
166000 USD
CY2011Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
174000 USD
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
20000 USD
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
45595000 USD
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
54923000 USD
CY2011Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-3000 USD
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
141000 USD
CY2012Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1746000 USD
CY2011Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1295000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2723000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3329000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
2090000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
3224000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4464000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5327000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
53000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
0 USD
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
CY2010 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2011Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2012 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M13D
CY2011Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2011Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2011 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
85000 USD
CY2010 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-79000 USD
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
165000 USD
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6785000 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3495000 USD
CY2012Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9400000 USD
CY2012 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P6Y
CY2011Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8434000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
11942000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3374000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
0 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2812000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3374000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3374000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24876000 USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24876000 USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16442000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12934000 USD
CY2011 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-706000 USD
CY2010 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-314000 USD
CY2012 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-348000 USD
CY2010 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-148000 USD
CY2011 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-49000 USD
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1551000 USD
CY2011Q4 us-gaap Goodwill
Goodwill
3241000 USD
CY2012Q4 us-gaap Goodwill
Goodwill
3241000 USD
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-30587000 USD
CY2010 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-8157000 USD
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16309000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5442000 USD
CY2011Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3313000 USD
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7293000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2140000 USD
CY2011Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5123000 USD
CY2012Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-15712000 USD
CY2011Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5205000 USD
CY2011Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2668000 USD
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
270000 USD
CY2010 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
384000 USD
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
241000 USD
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9716000 USD
CY2010 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1664000 USD
CY2011 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5814000 USD
CY2011 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0 USD
CY2010 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0 USD
CY2012 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
1493000 USD
CY2012 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
7000 USD
CY2010 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
117000 USD
CY2011 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-252000 USD
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5708000 USD
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-10399000 USD
CY2010 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2858000 USD
CY2010 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
630000 USD
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
204000 USD
CY2011 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
650000 USD
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
312000 USD
CY2011 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1241000 USD
CY2010 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1020000 USD
CY2011 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1421000 USD
CY2010 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-245000 USD
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1063000 USD
CY2012 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
0 USD
CY2011 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
83000 USD
CY2010 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-56000 USD
CY2012 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
126000 USD
CY2011 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
89000 USD
CY2010 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
336000 USD
CY2010 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2105000 USD
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1156000 USD
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6710000 USD
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3583000 USD
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-11372000 USD
CY2010 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8087000 USD
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1789000 USD
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4339000 USD
CY2010 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-15131000 USD
CY2012 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3290000 USD
CY2011 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1322000 USD
CY2010 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1589000 USD
CY2011 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1671000 USD
CY2010 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-98000 USD
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3186000 USD
CY2012 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
197000 USD
CY2011 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
4351000 USD
CY2010 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-6048000 USD
CY2010 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2814000 USD
CY2011 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-513000 USD
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1330000 USD
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3051000 USD
CY2010 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-13000 USD
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
682000 USD
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
CY2010 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
735000 USD
CY2011 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
45000 USD
CY2012 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2010 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
179672000 shares
CY2011 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2010 us-gaap Interest Expense
InterestExpense
529000 USD
CY2012 us-gaap Interest Expense
InterestExpense
0 USD
CY2011 us-gaap Interest Expense
InterestExpense
0 USD
CY2010 us-gaap Interest Paid
InterestPaid
350000 USD
CY2012 us-gaap Interest Paid
InterestPaid
0 USD
CY2011 us-gaap Interest Paid
InterestPaid
0 USD
CY2011Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1655000 USD
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
662000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
1302000 USD
CY2011Q4 us-gaap Inventory Net
InventoryNet
4488000 USD
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
588000 USD
CY2011Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2779000 USD
CY2011Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
54000 USD
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
52000 USD
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
252000 USD
CY2011 us-gaap Investment Income Interest
InvestmentIncomeInterest
273000 USD
CY2010 us-gaap Investment Income Interest
InvestmentIncomeInterest
166000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99965000 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
135922000 USD
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28292000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16283000 USD
CY2012Q4 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
600000 USD
CY2011Q4 us-gaap Marketable Securities
MarketableSecurities
27720000 USD
CY2012Q4 us-gaap Marketable Securities
MarketableSecurities
13524000 USD
CY2012Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
3623000 USD
CY2011Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
10348000 USD
CY2012Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
24800000 USD
CY2011Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
18900000 USD
CY2012 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were incorporated in Delaware in January 2002. We engineer enzymes for pharmaceutical, biofuel and chemical production. Our proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have commercialized our technology and products in the pharmaceuticals market, which is our primary business focus. There are currently over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50</font><font style="font-family:inherit;font-size:10pt;"> pharmaceutical firms using our technology, products and services in their manufacturing process development, including in the production of some of the world's bestselling and fastest growing drugs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing our CodeXyme</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> cellulase enzymes to convert non-food plant material, which we call cellulosic biomass, into affordable sugars, which can then be converted into renewable fuels and chemicals. We are also developing our own manufacturing process for CodeXol</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> detergent alcohols, which are bio-based chemicals. Detergent alcohols are used to manufacture surfactants, which are key, active cleaning ingredients in consumer products such as shampoos, liquid soaps and laundry detergents. We are seeking collaboration partners to assist us with the development and commercialization of CodeXyme</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> cellulase enzymes and CodeXol</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> detergent alcohols, and we are also exploring other strategic options with respect to these products and technologies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We create our products by applying our CodeEvolver</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> directed evolution technology platform, which introduces genetic mutations into microorganisms, giving rise to changes in the enzymes that they produce. Once we identify potentially beneficial mutations, we test combinations of these mutations until we have created variant enzymes that exhibit marketable performance characteristics superior to competitive products. This process allows us to make continuous, efficient improvements to the performance of our enzymes. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In these Notes to Consolidated Financial Statements, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Codexis, Inc. and its subsidiaries on a consolidated basis.</font></div></div>
CY2010 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62239000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1257000 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2579000 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48808000 USD
CY2010 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5166000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16711000 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-490000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11892000 USD
CY2010 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16383000 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-30857000 USD
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-16550000 USD
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-8541000 USD
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-15539000 USD
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-2742000 USD
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-7490000 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-5519000 USD
CY2011Q1 us-gaap Net Income Loss
NetIncomeLoss
-3471000 USD
CY2011Q2 us-gaap Net Income Loss
NetIncomeLoss
-5040000 USD
CY2011Q4 us-gaap Net Income Loss
NetIncomeLoss
-5297000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-2309000 USD
CY2011Q4 us-gaap Noncurrent Assets
NoncurrentAssets
41592000 USD
CY2012Q4 us-gaap Noncurrent Assets
NoncurrentAssets
31821000 USD
CY2010Q4 us-gaap Noncurrent Assets
NoncurrentAssets
44401000 USD
CY2010 us-gaap Operating Expenses
OperatingExpenses
114228000 USD
CY2012 us-gaap Operating Expenses
OperatingExpenses
118811000 USD
CY2011 us-gaap Operating Expenses
OperatingExpenses
139772000 USD
CY2011Q3 us-gaap Operating Expenses
OperatingExpenses
35615000 USD
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
28497000 USD
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
28268000 USD
CY2011Q4 us-gaap Operating Expenses
OperatingExpenses
38397000 USD
CY2011Q2 us-gaap Operating Expenses
OperatingExpenses
31347000 USD
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
38386000 USD
CY2012Q4 us-gaap Operating Expenses
OperatingExpenses
23659000 USD
CY2011Q1 us-gaap Operating Expenses
OperatingExpenses
34413000 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-30513000 USD
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-15907000 USD
CY2010 us-gaap Operating Income Loss
OperatingIncomeLoss
-7124000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
20604000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3112000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2677000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3047000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3031000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2947000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
5790000 USD
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
972000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2237000 USD
CY2012 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
271000 USD
CY2010 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
218000 USD
CY2011 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-373000 USD
CY2012 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000 USD
CY2011 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
165000 USD
CY2010 us-gaap Other Expenses
OtherExpenses
1199000 USD
CY2011 us-gaap Other Expenses
OtherExpenses
675000 USD
CY2012 us-gaap Other Expenses
OtherExpenses
326000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3943000 USD
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3455000 USD
CY2011 us-gaap Other Noninterest Expense
OtherNoninterestExpense
-31000 USD
CY2012 us-gaap Other Noninterest Expense
OtherNoninterestExpense
-22000 USD
CY2010 us-gaap Other Noninterest Expense
OtherNoninterestExpense
-321000 USD
CY2012 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
CY2012 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2010 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3870000 USD
CY2011 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2010 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
20705000 USD
CY2012 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2011 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2011 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
52564000 USD
CY2010 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
49051000 USD
CY2012 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
20638000 USD
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10736000 USD
CY2010 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6990000 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2933000 USD
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
8500000 USD
CY2012 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
29885000 USD
CY2010 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
15000 USD
CY2012 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2010 us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
-8026000 USD
CY2011 us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
0 USD
CY2012 us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
0 USD
CY2010 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
70695000 USD
CY2010 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
72541000 USD
CY2010 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2012 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
68000 USD
CY2011 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2012Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2345000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5395000 USD
CY2011 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2010 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1594000 USD
CY2011 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2579000 USD
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1257000 USD
CY2011Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
55923000 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
50822000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16650000 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24176000 USD
CY2012 us-gaap Realized Gain Loss On Marketable Securities Cost Method Investments And Other Investments
RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
0 USD
CY2010 us-gaap Realized Gain Loss On Marketable Securities Cost Method Investments And Other Investments
RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
0 USD
CY2011 us-gaap Realized Gain Loss On Marketable Securities Cost Method Investments And Other Investments
RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
0 USD
CY2010 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
70196000 USD
CY2011 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
71368000 USD
CY2012 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
50127000 USD
CY2011Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
17486000 USD
CY2011Q2 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
17385000 USD
CY2012Q2 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
15868000 USD
CY2011Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
19201000 USD
CY2012Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
14612000 USD
CY2011Q4 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
17296000 USD
CY2012Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
18569000 USD
CY2012Q4 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
1078000 USD
CY2010 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52405000 USD
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56785000 USD
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61049000 USD
CY2011Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13750000 USD
CY2011Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14965000 USD
CY2012Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10594000 USD
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15650000 USD
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16349000 USD
CY2011Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15548000 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14191000 USD
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16786000 USD
CY2011Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
1511000 USD
CY2012Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
1511000 USD
CY2012Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
173 employee
CY2011 us-gaap Results Of Operations Accretion Of Asset Retirement Obligations
ResultsOfOperationsAccretionOfAssetRetirementObligations
39000 USD
CY2012 us-gaap Results Of Operations Accretion Of Asset Retirement Obligations
ResultsOfOperationsAccretionOfAssetRetirementObligations
30000 USD
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-184699000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215556000 USD
CY2010 us-gaap Revenue From Grants
RevenueFromGrants
4073000 USD
CY2012 us-gaap Revenue From Grants
RevenueFromGrants
2247000 USD
CY2011 us-gaap Revenue From Grants
RevenueFromGrants
3476000 USD
CY2012Q3 us-gaap Revenue From Grants
RevenueFromGrants
632000 USD
CY2011Q2 us-gaap Revenue From Grants
RevenueFromGrants
273000 USD
CY2011Q1 us-gaap Revenue From Grants
RevenueFromGrants
616000 USD
CY2012Q4 us-gaap Revenue From Grants
RevenueFromGrants
0 USD
CY2011Q3 us-gaap Revenue From Grants
RevenueFromGrants
1882000 USD
CY2011Q4 us-gaap Revenue From Grants
RevenueFromGrants
705000 USD
CY2012Q2 us-gaap Revenue From Grants
RevenueFromGrants
258000 USD
CY2012Q1 us-gaap Revenue From Grants
RevenueFromGrants
1357000 USD
CY2011 us-gaap Revenues
Revenues
123865000 USD
CY2010 us-gaap Revenues
Revenues
107104000 USD
CY2012 us-gaap Revenues
Revenues
88298000 USD
CY2011Q3 us-gaap Revenues
Revenues
33282000 USD
CY2012Q4 us-gaap Revenues
Revenues
7912000 USD
CY2012Q2 us-gaap Revenues
Revenues
22909000 USD
CY2012Q1 us-gaap Revenues
Revenues
31136000 USD
CY2012Q3 us-gaap Revenues
Revenues
26341000 USD
CY2011Q4 us-gaap Revenues
Revenues
33494000 USD
CY2011Q1 us-gaap Revenues
Revenues
31034000 USD
CY2011Q2 us-gaap Revenues
Revenues
26055000 USD
CY2010Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
13.00
CY2010 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
32835000 USD
CY2011 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
49021000 USD
CY2012 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
35924000 USD
CY2011Q2 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
8397000 USD
CY2012Q1 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
15167000 USD
CY2011Q4 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
15493000 USD
CY2011Q3 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
12199000 USD
CY2012Q2 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
6783000 USD
CY2011Q1 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
12932000 USD
CY2012Q4 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
6834000 USD
CY2012Q3 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
7140000 USD
CY2010 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
33841000 USD
CY2012 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31379000 USD
CY2011 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36942000 USD
CY2011Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9782000 USD
CY2012Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9395000 USD
CY2011Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8871000 USD
CY2011Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9276000 USD
CY2012Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6789000 USD
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7909000 USD
CY2012Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7286000 USD
CY2011Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9013000 USD
CY2010 us-gaap Share Based Compensation
ShareBasedCompensation
8737000 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
5076000 USD
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
9431000 USD
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1122311 shares
CY2012Q4 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
54000 USD
CY2012 us-gaap Stock Issued During Period Shares Issued For Cash
StockIssuedDuringPeriodSharesIssuedForCash
3308 shares
CY2010Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6000000 shares
CY2010 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
179672000 USD
CY2010 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
67711000 USD
CY2010Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
67700000 USD
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2579000 USD
CY2010 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1594000 USD
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1257000 USD
CY2010 cdxs Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
0 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
78440000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
102690000 USD
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
107361000 USD
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
-144845000 USD
CY2012Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
1000000 USD
CY2010 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
255000 USD
CY2011 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-370000 USD
CY2012 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-647000 USD
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6611000 USD
CY2010Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6492000 USD
CY2009Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5899000 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7429000 USD
CY2010 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2011 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
262000 USD
CY2012 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
29000 USD
CY2011Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
239000 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
250000 USD
CY2012 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
11000 USD
CY2011 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
39000 USD
CY2010 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
75000 USD
CY2011 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
470000 USD
CY2010 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
593000 USD
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
718000 USD
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
316000 USD
CY2011 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
4000 USD
CY2010 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2011 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
93000 USD
CY2012 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
187000 USD
CY2010 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1500000 USD
CY2011Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1400000 USD
CY2012 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Our management regularly assesses these estimates which primarily affect revenue recognition, the valuation of marketable securities and accounts receivable, intangible assets, goodwill arising out of business acquisitions, inventories, accrued liabilities, common stock, and stock options and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.</font></div></div>
CY2011Q4 us-gaap Valuation Allowance Amount
ValuationAllowanceAmount
63128000 USD
CY2012Q4 us-gaap Valuation Allowance Amount
ValuationAllowanceAmount
71692000 USD
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8600000 USD
CY2011 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5800000 USD
CY2010 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1600000 USD
CY2012Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
260000 USD
CY2011Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
266000 USD
CY2010 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24594000 shares
CY2011 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35674000 shares
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36768000 shares
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36768000 shares
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35674000 shares
CY2010 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24594000 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37118000 shares
CY2011Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35116000 shares
CY2011Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35965000 shares
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36057000 shares
CY2011Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35919000 shares
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36296000 shares
CY2012Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37581000 shares
CY2011Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35685000 shares
CY2012 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2010 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
3000 shares
CY2011 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36768000 shares
CY2010 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24597000 shares
CY2011 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35674000 shares
CY2010 cdxs Adjustments To Additional Paid In Capital Non Employee Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalNonEmployeeShareBasedCompensation
386000 USD
CY2011 cdxs Adjustments To Additional Paid In Capital Non Employee Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalNonEmployeeShareBasedCompensation
387000 USD
CY2012 cdxs Adjustments To Additional Paid In Capital Non Employee Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalNonEmployeeShareBasedCompensation
104000 USD
CY2010 cdxs Cash Paid In Lieu Of Partial Shares
CashPaidInLieuOfPartialShares
1000 USD
CY2012Q1 cdxs Change In Accounting Estimate Financial Effect Additional Revenue Related To Prior Years
ChangeInAccountingEstimateFinancialEffectAdditionalRevenueRelatedToPriorYears
1000000 USD
CY2012Q4 cdxs Common Stock Reserved For Future Issuance Value
CommonStockReservedForFutureIssuanceValue
11118000 USD
CY2011Q4 cdxs Common Stock Reserved For Future Issuance Value
CommonStockReservedForFutureIssuanceValue
10223000 USD
CY2011 cdxs Comprehensive Loss
ComprehensiveLoss
-16923000 USD
CY2010 cdxs Comprehensive Loss
ComprehensiveLoss
-8323000 USD
CY2012 cdxs Comprehensive Loss
ComprehensiveLoss
-30586000 USD
CY2012Q4 cdxs Deferred Tax Assets Research Credit Extension
DeferredTaxAssetsResearchCreditExtension
400000 USD
CY2012 cdxs Defined Contribution Plan Employer Contribution Amount
DefinedContributionPlanEmployerContributionAmount
0 USD
CY2011 cdxs Defined Contribution Plan Employer Contribution Amount
DefinedContributionPlanEmployerContributionAmount
0 USD
CY2010 cdxs Defined Contribution Plan Employer Contribution Amount
DefinedContributionPlanEmployerContributionAmount
0 USD
CY2012 cdxs Defined Contribution Plan Minimum Employee Eligibility Age
DefinedContributionPlanMinimumEmployeeEligibilityAge
P18Y
CY2010 cdxs Exercise Of Common Warrants Shares
ExerciseOfCommonWarrantsShares
0 shares
CY2012 cdxs Exercise Of Common Warrants Shares
ExerciseOfCommonWarrantsShares
0 shares
CY2010 cdxs Extinguishment Of Royalty Payable
ExtinguishmentOfRoyaltyPayable
461000 USD
CY2012 cdxs Extinguishment Of Royalty Payable
ExtinguishmentOfRoyaltyPayable
0 USD
CY2011 cdxs Extinguishment Of Royalty Payable
ExtinguishmentOfRoyaltyPayable
0 USD
CY2012 cdxs Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
165000 USD
CY2010 cdxs Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-37000 USD
CY2011 cdxs Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-3000 USD
CY2011 cdxs Gain From Extinguishment Of Asset Retirement Obligation
GainFromExtinguishmentOfAssetRetirementObligation
-124000 USD
CY2012 cdxs Gain From Extinguishment Of Asset Retirement Obligation
GainFromExtinguishmentOfAssetRetirementObligation
-212000 USD
CY2010 cdxs Gain From Extinguishment Of Asset Retirement Obligation
GainFromExtinguishmentOfAssetRetirementObligation
0 USD
CY2012 cdxs Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
753000 USD
CY2011 cdxs Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
0 USD
CY2011Q4 cdxs Marketable Securities Aggregated Unrealized Loss Amount
MarketableSecuritiesAggregatedUnrealizedLossAmount
46000 USD
CY2011Q4 cdxs Marketable Securities Fair Value
MarketableSecuritiesFairValue
18500000 USD
CY2011Q4 cdxs Number Of Marketable Securities
NumberOfMarketableSecurities
14 securities
CY2012Q4 cdxs Number Of Marketable Securities
NumberOfMarketableSecurities
0 securities
CY2011 cdxs Number Of Months In Unrealized Loss Position
NumberOfMonthsInUnrealizedLossPosition
P12M
CY2012 cdxs Number Of Pharmaceutical Firms Using Technology
NumberOfPharmaceuticalFirmsUsingTechnology
50 Entity
CY2011 cdxs Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax Portion Attributable To Parent Reclassification Of Losses Included Net Loss
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentReclassificationOfLossesIncludedNetLoss
0 USD
CY2010 cdxs Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax Portion Attributable To Parent Reclassification Of Losses Included Net Loss
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentReclassificationOfLossesIncludedNetLoss
0 USD
CY2012 cdxs Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax Portion Attributable To Parent Reclassification Of Losses Included Net Loss
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentReclassificationOfLossesIncludedNetLoss
753000 USD
CY2010 cdxs Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
1605000 USD
CY2012 cdxs Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
10397000 USD
CY2011 cdxs Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
6037000 USD
CY2012 cdxs Property Plant And Equipment Leasehold Improvements Increase In Remaining Useful Life Maximum
PropertyPlantAndEquipmentLeaseholdImprovementsIncreaseInRemainingUsefulLifeMaximum
P5Y
CY2011Q1 cdxs Property Plant And Equipment Leasehold Improvements Net Book Value
PropertyPlantAndEquipmentLeaseholdImprovementsNetBookValue
2300000 USD
CY2011 cdxs Reclassification Preferred Stock Warrant From Liability To Additional Paid In Capital
ReclassificationPreferredStockWarrantFromLiabilityToAdditionalPaidInCapital
0 USD
CY2012 cdxs Reclassification Preferred Stock Warrant From Liability To Additional Paid In Capital
ReclassificationPreferredStockWarrantFromLiabilityToAdditionalPaidInCapital
0 USD
CY2010 cdxs Reclassification Preferred Stock Warrant From Liability To Additional Paid In Capital
ReclassificationPreferredStockWarrantFromLiabilityToAdditionalPaidInCapital
2686000 USD
CY2011 cdxs Revaluation Of Redeemable Convertible Preferred Stock Warrant Liability
RevaluationOfRedeemableConvertiblePreferredStockWarrantLiability
0 USD
CY2010 cdxs Revaluation Of Redeemable Convertible Preferred Stock Warrant Liability
RevaluationOfRedeemableConvertiblePreferredStockWarrantLiability
677000 USD
CY2012 cdxs Revaluation Of Redeemable Convertible Preferred Stock Warrant Liability
RevaluationOfRedeemableConvertiblePreferredStockWarrantLiability
0 USD
CY2012 cdxs Share Based Compensation Arrangement By Share Based Payment Award Expiration Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod
P10Y
CY2012 cdxs Stock Issued During Period Value Cancellation
StockIssuedDuringPeriodValueCancellation
65000 USD
CY2012Q4 cdxs Undiscounted Cash Flow Calculation Capitalization Factor
UndiscountedCashFlowCalculationCapitalizationFactor
6.25
CY2012 cdxs Unrealized Loss Position Period
UnrealizedLossPositionPeriod
Less than 12 months
CY2010 cdxs Vesting Of Shares Early Exercised
VestingOfSharesEarlyExercised
13000 USD
CY2012 dei Amendment Flag
AmendmentFlag
false
CY2012 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2012 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012 dei Document Period End Date
DocumentPeriodEndDate
2012-12-31
CY2012 dei Document Type
DocumentType
10-K
CY2012 dei Entity Central Index Key
EntityCentralIndexKey
0001200375
CY2013Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38009688 shares
CY2012 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2012Q2 dei Entity Public Float
EntityPublicFloat
102400000 USD
CY2012 dei Entity Registrant Name
EntityRegistrantName
CODEXIS INC
CY2012 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2012 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No

Files In Submission

Name View Source Status
0001445305-13-000770-index-headers.html Edgar Link pending
0001445305-13-000770-index.html Edgar Link pending
0001445305-13-000770.txt Edgar Link pending
0001445305-13-000770-xbrl.zip Edgar Link pending
cdxs-20121231.xml Edgar Link completed
cdxs-20121231.xsd Edgar Link pending
cdxs-20121231x10k.htm Edgar Link pending
cdxs-20121231x10kxex311.htm Edgar Link pending
cdxs-20121231x10kxex312.htm Edgar Link pending
cdxs-20121231x10kxex321.htm Edgar Link pending
cdxs-20121231_cal.xml Edgar Link unprocessable
cdxs-20121231_def.xml Edgar Link unprocessable
cdxs-20121231_lab.xml Edgar Link unprocessable
cdxs-20121231_pre.xml Edgar Link unprocessable
cdxs2012123110kchart.jpg Edgar Link pending
exhibit1025sitagliptinsupp.htm Edgar Link pending
exhibit1026aexelalicenseag.htm Edgar Link pending
exhibit1026bamendmenttoexe.htm Edgar Link pending
exhibit1027mhoofferletter2.htm Edgar Link pending
exhibit105karchenzymesuppl.htm Edgar Link pending
exhibit231consentofindepen.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending